References
1. Cranmer H, et al. Brentuximab Vedotin PLUS CHP in Frontline Systemic Anaplastic Large Cell Lymphoma (SALCL)- Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Retreatment with Brentuximab Vedotin. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN128, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/108727
2. Zou D, et al. Cost-Effectiveness of Brentuximab Vedotin for the Frontline Treatment of Peripheral T-Cell Lymphomas in Canada. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN71, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/107348
3. Paquete AT, et al. Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin in Combination with Daunorubicin and Cytarabine for the Treatment of Acute Myeloid Leukaemia in Portugal. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN264, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/108088
4. van Oostrum I, et al. Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy and Blinatumomab for Treating Relapsed Refractory ACUTE Lymphoblastic Leukaemia Patients in the Netherlands. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN68, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/107799
5. van Oostrum I, et al. Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN67, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/107833
6. Mazaleyrat B, et al. Cost Effectiveness of Obinutuzumab PLUS Chemotherapy Followed By Obinutuzumab Maintenance for Patient with Previously Untreated Advanced-STAGE Follicular Lymphoma in French Setting. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN164, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/106443
Rights and permissions
About this article
Cite this article
Cost-effective options for haematological cancers investigated at ISPOR. PharmacoEcon Outcomes News 868, 9–10 (2020). https://doi.org/10.1007/s40274-020-7341-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7341-0